Vital Biopharmaceutical Insights and Analytics

for Experts from Experts

Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.

Learn More

Niche Markets and Rare Diseases: Huntington’s Disease

Three therapies, Teva’s Huntexil, Auspex’s SD-809 and Raptor’s Procysbi, will likely receive regulatory approval for Huntington’s disease in the United States and the EU5 markets... Learn More

Novel Oral Anticoagulants in Brazil and Mexico: How to Maximize Current Usage and Gain Patient Shares Over Conventional Anticoagulants

Join us live on September 10, 2014... Learn More

View Webinar schedule and archive

Search Reports


See which reports have been searched on the most.


In the Spotlight

Join us in Boston

Come join us for an exciting one-day seminar.
Hear in-depth analysis of hot topics and trends concerning global oncology while engaging directly with Decision Resources Group analysts.

View the Agenda  |  Meet our expert speakers

Recent Reports [ view all ]

  • Hospital-Treated Gram-Negative Infections - 2014

    Gram-negative infections (GNIs) comprise a large portion of hospital-treated infections (HTIs), which represent a... Read More

  • Alzheimer's Disease - 2014

    Last Updated 28 August 2014
    The market for Alzheimer’s disease (AD) pharmacotherapies continues to offer... Read More

  • Treatment Algorithms in Diabetic Macular Edema

    Diabetic retinopathy (DR) is characterized by progressive damage to the blood vessels in the retina of a diabetic... Read More

Decision Resources Group brands include: